Search Results
Curing AML in Elderly Patients
Robert Hromas, M.D., a blood cancer expert at the University of Florida's College of Medicine, is looking to discover new drugs that will improve the response of elderly AML patients to chemotherapy. His latest research, funded through a Translational Research Program grant from The Leukemia & Lymphoma Society, focuses on inhibiting the DNA repair response.
My Myeloma Story
“What is multiple myeloma?” Those were my words after the doctor’s review of my lab results for a routine and random high blood pressure exam in November 2008.
Striving for Social Justice, Racial Equality and Diversity
As a patient focused organization, we stand for:
- All cancer patients, working to ensure they have access to quality affordable care.
- Racial justice and equality for Black people.
- Diversity and inclusion among our staff and volunteers.
We stand against hate, prejudice and injustice.
New Study Shows 9/11 Responders Have Higher Rates of Leukemia
All 9/11 responders put their own lives at risk to save others from the events that occurred at the World Trade Center (WTC) on September 11, 2001, in New York City. Since then, several studies have shown elevated rates of cancers such as multiple myeloma, prostate cancer and thyroid cancer among first responders and those who worked nearby.
Surviving ALL: An Intimate Look at How Cancer Affected the Careers, Relationships & Fertility of Four Young Adults
A cancer diagnosis is a devastating blow for people of all ages, but presents special challenges for young adults. This period of life is usually a time of transition as they are embarking on journeys such as school, relationships and careers. A cancer diagnosis can bring their lives to a screeching halt in the midst of these new adventures.
Looking Ahead: LLS Panel Highlights Trends and Advances
The Leukemia & Lymphoma Society recently brought together a world-renowned panel of thought leaders to discuss the latest advances and insights into blood cancer research and treatment, drug costs and patient access, and patient advocacy and policy.
“There’s never a good time to get cancer but this is a phenomenal time to be fighting it,” said Louis J. DeGennaro, president and CEO of The Leukemia & Lymphoma Society (LLS).
3 Insights from a Clinical Trial Patient
The road to finding new and better cancer treatments often includes an important step: clinical trials. For patients with hard-to-treat diseases, these studies can be superhighways to the right treatment. A clinical trial can tell oncologists whether a new treatment works, how certain cancer types affect the body, and more.
Etoposide
Etoposide is used to treat people who have certain types of blood cancer including Hodgkin and non-Hodgkin lymphoma. It is FDA approved for some types of lung and testicular cancer. This medicine often causes a temporary loss of hair. After treatment with etoposide has ended, normal hair growth should return.
Significant Advance for Hodgkin Lymphoma Patients
The Food & Drug Administration’s accelerated approval of an immunotherapy for patients with Hodgkin lymphoma who have failed other treatments is a positive development for patients who face a very poor prognosis.
While Hodgkin lymphoma is now considered one of the most curable forms of cancer – with a more than 86 percent five-year-survival rate overall – those patients who relapse after treatment have a much reduced chance of survival.
Eight Years and Counting: "The Pill"
I never would have imagined that I could stave off a deadly blood cancer by taking a pill. Yet that's exactly what I -- and thousands of others with chronic myeloid leukemia (CML) -- do every day. That little orange tablet known as Gleevec (imatinib) has led us back to normalcy. As a breast cancer survivor with many friends and family members waging their own cancer battles, I only wish there were more solutions this simple -- and this hopeful.
The Impossible Choice: The Role of Insurance Design on Financial Toxicity and Access to Care for Individuals with Blood Cancer
The overall goal of this project is to understand the role of insurance design on financial toxicity and access to care among individuals with blood cancer. To understand this interplay, we will use a unique and innovative linkage of the 2012-2019 Colorado Cancer Registry (CCR) to the 2013-2021 Colorado All-Payer Claims Database and the LexisNexis and TranUnion financial and life event databases.
3 Things You Might Like to Know About Being Newly Diagnosed
A cancer diagnosis is a pivotal moment in a person’s lifetime.
From that point forward, it’s a part of who you are. It shapes how you think about the world—through the lens of your diagnosis and what’s important to you.
Targeted Therapy focus of LLS-hosted Symposium at ASH
As researchers gain greater understanding of how cancer works, they are becoming more adept at developing precisely targeted therapies that go after the tumor cells while sparing the healthy cells.
Today The Leukemia & Lymphoma Society (LLS) kicked off the 57th American Society of Hematology (ASH) Annual Meeting in Orlando with a satellite symposium entitled, “Molecularly Targeted Therapies for Hematologic Malignancies.”
FDA Approves First CAR T-Immunotherapy for Relapsed/Refractory Acute Lymphoblastic Leukemia
The U.S. Food and Drug Administration (FDA) recently announced approval of brexucabtagene autoleucel (Tecartus®) as the first and only CAR T-cell treatment for adults with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). Roughly half of all ALL cases occur in adults, and unlike pediatric ALL, adults have historically had a poor prognosis. This approval, which follows an FDA Breakthrough Therapy Designation and priority review, is a meaningful advance for these patients.
Impact of Insurance Type and Cost Sharing on Equity in Access to Oral Anticancer Medications for Blood Cancers
This project will evaluate the association of insurance type with insurer rejection and patient abandonment of new OAM prescriptions for blood cancers, overall and by sociodemographic factors. It will also evaluate the association of cost sharing with patient abandonment of OAM prescriptions for blood cancers and conduct simulations under alternative cost sharing scenarios to inform policy reform proposals among commercially insured enrollees.Just Diagnosed? LLS Can Help
Finding out you have blood cancer can bring on a whirlwind of emotions and a plethora of questions. No one expects to get such a diagnosis and there isn’t anything you can do to prepare.
Regardless of how you came to your diagnosis, most people report not having absorbed a lot of information after hearing the word “cancer." The vocabulary may seem like a foreign language, and the need for support can be tremendous.
